加载中
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
前收盘价
US$5.50
−US$0.17 · -3.00%
盘后
US$5.50
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
日内区间
当前US$5.50
52周区间
当前US$5.50
盘中时间采用ET。市场数据可能有所延迟。
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
日内区间
当前US$5.50
52周区间
当前US$5.50
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2542.1万 USD | 2.11亿 USD | 1.29亿 USD | — | — |
| 销货成本 | 409.6万 USD | — | — | — | — |
| 毛利 | 2132.5万 USD | 2.11亿 USD | 1.29亿 USD | — | — |
| 研究与开发 | 1.42亿 USD | 1.25亿 USD | 9988.4万 USD | 6660.9万 USD | 3592.6万 USD |
| 销售、一般及管理费用 | 4105万 USD | 3846.5万 USD | 3229.1万 USD | 3063.9万 USD | 1520.1万 USD |
| 营业费用 | 1.77亿 USD | 1.64亿 USD | 1.32亿 USD | 9724.8万 USD | 5112.7万 USD |
| 利息收入 | — | 1947.4万 USD | 1521.8万 USD | 263.2万 USD | — |
| 利息支出 | — | — | — | 263.2万 USD | — |
| 折旧和摊销 | 409.6万 USD | 377.3万 USD | 284.1万 USD | 189.5万 USD | 111.7万 USD |
| 营业利润 | −1.56亿 USD | 4701.1万 USD | −316.2万 USD | −9724.8万 USD | −5112.7万 USD |
| 净利润 | −1.44亿 USD | 6562.6万 USD | −668.5万 USD | −9461.6万 USD | −5115.8万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
